Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SynthBiome has developed and commercialized highly accurate synthetic growth media that replicate the physiological conditions of chronic infections such as cystic fibrosis lung infections. Their SCFM1 and SCFM2 products are used by researchers to better model bacterial behavior in human-like environments, improving preclinical drug development and treatment selection. The company’s technology enables more predictive antibiotic testing compared to traditional in vitro or animal models
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on SynthBiome.